Lundbeck Announces Board Changes as Strategic Focus on Growth Evolves

Board Changes at H. Lundbeck A/S

Lundbeck, the renowned biopharmaceutical company dedicated to brain health, has announced key changes to its Board of Directors as part of a strategic transition. Dorothea Wenzel, who has been serving as the Chair of the Board, confirmed that she will be stepping down during the Annual General Meeting (AGM) scheduled for 2027. This decision comes after a significant tenure where she has played a pivotal role since joining the Lundbeck Board in 2021.

Her leadership has been characterized by transformative changes that have positioned the company for future growth. Under her guidance, Lundbeck has not only strengthened its commercial performance but also advanced its developmental pipeline, gearing up to embrace the next phase of its Focused Innovator strategy. This new phase, aptly termed the Scale phase, aims to leverage past achievements and propel Lundbeck into sustainable long-term growth.

With Wenzel's exit, the Board has expressed its intention to appoint Lars Fruergaard Jørgensen as the new Chair. Jørgensen will officially join the Board as an observer starting November 10, 2026, before assuming the role as Chair at the AGM 2027, pending shareholder approval. Jørgensen is an accomplished executive in the pharmaceutical industry, boasting over 30 years of experience, including a successful tenure as President and CEO of Novo Nordisk from 2017 to 2025. His leadership style and strategic insights are expected to bring valuable contributions to Lundbeck’s ambitious future plans.

During his time as CEO at Novo Nordisk, Jørgensen ushered the company through a period of substantial growth in both diabetes care and obesity treatments, establishing his reputation as a formidable leader in the pharmaceutical field. His resume also includes significant roles such as President of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and a leadership position at Healthcare Denmark. Furthermore, he holds a Master's degree in Finance and Business Administration from Aarhus University.

Lene Skole, Lundbeck's Vice Chair, conveyed gratitude towards Wenzel for her outstanding commitment over the years, noting that her contributions have significantly strengthened the company. She emphasized that Lundbeck is now well-prepared for its next chapter and expressed confidence in Jørgensen's ability to further the company’s goals.

Reflecting on her tenure, Wenzel expressed pride in the advancements made by Lundbeck during her leadership. She highlighted that these pivotal changes were undertaken collectively with the Board, the company's management, and its dedicated employees. As Lundbeck sets its sights on future strategies, she believes that this is the right moment to transition leadership, setting the stage for ongoing success.

In response to his upcoming role, Jørgensen noted his enthusiasm for leading Lundbeck at such a crucial juncture. He remarked on the company's robust foundation in brain health, highlighting its successful business model and promising late-stage pipeline. Jørgensen is poised to steer Lundbeck through its next phase of growth, with a focus on enhancing patient care and upholding the interests of employees and shareholders alike.

As these changes unfold, the upcoming AGM will also include nominations for other Board members, solidifying Lundbeck's governance structure as it embarks on its new strategic journey. The company's commitment to advancing brain health remains unwavering, with aspirations to pioneer medicines that address some of the most challenging neurological conditions.

In conclusion, the strategic shifts at H. Lundbeck A/S illustrate a committed approach to enhancing leadership and maintaining growth momentum. With a team poised for innovation and sustainability, Lundbeck is set to make significant strides in the field of brain health in the coming years.